Table 3.

Sensitivity/specificity for TRIM21, NY-ESO-1, TP53, and PAX8, Validation I

	Late stage HGSOC (n = 50)	Early stage HGSOC (n = 14)	Late and early stage HGSOC (n = 64)	Benign (n = 50)	Healthy (n = 50)	Benign and healthy (n = 100)
Positive threshold = 2
Antigen	Sensitivity	Sensitivity	Sensitivity	Specificity	Specificity	Specificity
TRIM21	0.34	0.29	0.33	0.90	1.00	0.95
TP53	0.28	0.14	0.25	0.98	0.96	0.97
NYESO1	0.24	0.29	0.25	0.98	0.98	0.98
PAX8	0.10	0.14	0.11	0.96	1.00	0.98
HARS	0.06	0.29	0.11	0.90	0.98	0.94
CDR2L	0.06	0.14	0.08	0.94	0.96	0.95
CDR2	0.10	0.14	0.11	0.88	0.96	0.92
COR	0.02	0.00	0.02	1.00	0.96	0.98
TRIM21, TP53, NYESO1	0.64	0.43	0.59	0.86	0.94	0.90
TRIM21, TP53, NYESO1, PAX8	0.72	0.50	0.67	0.82	0.94	0.88
Positive threshold = 3
Antigen	Sensitivity	Sensitivity	Sensitivity	Specificity	Specificity	Specificity
TRIM21	0.28	0.21	0.27	0.92	1.00	0.96
TP53	0.26	0.14	0.23	1.00	0.98	0.99
NYESO1	0.22	0.29	0.23	1.00	1.00	1.00
PAX8	0.04	0.00	0.03	0.96	1.00	0.98
HARS	0.02	0.21	0.06	0.98	1.00	0.99
CDR2L	0.02	0.14	0.05	0.96	1.00	0.98
CDR2	0.06	0.14	0.08	0.94	0.98	0.96
COR	0.02	0.00	0.02	1.00	0.96	0.98
TRIM21, TP53, NYESO1	0.58	0.36	0.53	0.94	0.98	0.96
TRIM21, TP53, NYESO1, PAX8	0.62	0.36	0.56	0.88	0.98	0.93

Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, PAX8, HARS, CDR2L, CDR2, and CORTACTIN. Threshold (2) = Mean + 2 (StdDev) for healthy controls, threshold (3) = Mean + 3 (StdDev) for healthy controls.